[Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].

Chao Li, Suxia Geng, Minming Li, Fang Su, Xiaomei Chen, Chengxin Deng, Xin Huang, Peilong Lai, Jianyu Weng, Xin DuPubMed 2020 · DOI

Abstract

The expression of BTLA and its ligand HVEM, the proportion of T lymphocytes and the expression of BTLA on the surface of γδ T cells in patients with CMML are reduced. The effects of these abnormalities on T cell function and prognosis and efficacy of patients need to be further observed.
BibTeX
@inproceedings{li2020expression,
  author = {Chao Li and Suxia Geng and Minming Li and Fang Su and Xiaomei Chen and Chengxin Deng and Xin Huang and Peilong Lai and Jianyu Weng and Xin Du},
  title = {{[Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].}},
  booktitle = {PubMed},
  year = {2020},
  doi = {10.19746/j.cnki.issn.1009-2137.2020.01.010},
}

Loading related content...

Figure